SCHEDULE: BlackRock Boosts Stake in 4D Molecular Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has reported a 6.6% beneficial ownership in 4D Molecular Therapeutics, Inc. common stock as of September 30, 2025.
Summary
- BlackRock, Inc. beneficially owns 3,062,596 shares of 4D Molecular Therapeutics, Inc. common stock.
- This represents 6.6% of the total outstanding common stock of 4D Molecular Therapeutics, Inc.
- BlackRock, Inc. holds sole voting power over 2,988,740 shares.
- BlackRock, Inc. holds sole dispositive power over 3,062,596 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- BlackRock Investment Management, LLC, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares.
Sentiment
Score: 7
Explanation: BlackRock's significant beneficial ownership of 6.6% in 4D Molecular Therapeutics, Inc. common stock indicates continued institutional confidence, though the filing itself is a routine ownership disclosure and does not provide operational or financial performance updates.
Positives
- BlackRock, Inc.'s significant beneficial ownership of 6.6% indicates continued institutional confidence in 4D Molecular Therapeutics, Inc.
- The acquisition of shares was stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.
Management Comments
- "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."
Industry Context
BlackRock, Inc. is one of the world's largest asset managers, and its significant stake in 4D Molecular Therapeutics, Inc. (likely a biotechnology or pharmaceutical company given its name) reflects ongoing institutional investment interest in the life sciences sector. Such filings are routine disclosures of major institutional holdings, providing transparency into market participants' positions.
Stakeholder Impact
- Shareholders of 4D Molecular Therapeutics, Inc. may view BlackRock's substantial and continued stake as a positive indicator of institutional confidence and long-term value potential.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previous Power of Attorney, which was subsequently revoked. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 09/30/2025 | Date of the event which required the filing of this Schedule 13G statement. |
| 10/17/2025 | Date the Schedule 13G statement was signed by BlackRock, Inc. |
Recommendation
holdThe filing indicates a substantial institutional stake by BlackRock, Inc., which can be viewed as a positive signal of confidence in 4D Molecular Therapeutics, Inc. However, as a Schedule 13G, it does not provide financial performance or strategic updates to warrant a stronger recommendation. Investors should consider this as a data point supporting a 'hold' position while awaiting further operational or financial disclosures.
Keywords
BlackRock, 4D Molecular Therapeutics, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.